A Agilent Technologies Inc.

Agilent Announces CrossLab Group Leadership Transition

Agilent Technologies Inc. (NYSE: A) today announced that Mark Doak, Agilent senior vice president and president of the Agilent CrossLab Group, has decided to retire on May 1, 2020. The company has named Padraig McDonnell, currently vice president and general manager, Chemistries and Supplies Division, to succeed him. Doak will continue as an active member of the executive staff until his retirement date, working with McDonnell to ensure a smooth transition.

Mark Doak has had a successful 42-year career in the analytical and scientific-instrument industry. He started his career with Beckman Instruments and later joined Hewlett-Packard (Agilent’s predecessor) in 1982. During his tenure with Agilent, he has held various senior-management positions across marketing, quality and services. Doak has led the Agilent CrossLab Group since 2014.

“Mark has been a key contributor to Agilent’s success for many years,” said Mike McMullen, Agilent president and CEO. “His leadership, knowledge and drive have helped make Agilent the industry leader it is today. I personally want to thank Mark for all that he has done to help lead our company and wish him all the best in his retirement.

“I’m also extremely pleased that Padraig McDonnell has accepted the role of leading our CrossLab Group upon Mark’s retirement. His history as a key member of Mark’s team, combined with his broad-based experience, track record of results and outstanding leadership skills, make Padraig the ideal person to take on this assignment. I have the utmost confidence he will continue to produce the same high level of success that Mark has achieved.”

McDonnell has been with Agilent for 22 years and has served in a variety of key sales and business-unit leadership positions. Prior to his current role leading the Chemistries and Supplies Division for the past three years, McDonnell was the vice president and general manager of Agilent’s Life Science and Applied Markets Group for Europe, the Middle East and India.

“While I was conflicted about retiring, Agilent and the Agilent CrossLab Group are in a solid position to continue their positive growth trajectories and the timing was right from an organizational perspective,” Doak said. “I look forward to working closely with Padraig in the coming months to help ensure a seamless transition.”

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the Agilent .

Follow Agilent on , , and .

EN
23/01/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch